Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23995928 | 1.00 | HSD11B1 (0.49) | HSD11B1SMN1; SMN2HTTL3MBTL1CYP2D6 | |
| SCHEMBL22142323 | 1.00 | HSD11B1 (0.49) | HSD11B1SMN1; SMN2HTTL3MBTL1CYP2D6 | |
| SCHEMBL3476998 | 0.91 | HSD11B1 (0.55) | HSD11B1SMN1; SMN2HTTL3MBTL1CYP2D6 | |
| SCHEMBL3478542 | 0.84 | SMN1; SMN2 (0.40) | HSD11B1SMN1; SMN2CYP2D6KMT2A | |
| SCHEMBL12437276 | 0.83 | HSD11B1 (0.41) | HSD11B1HTTL3MBTL1CYP2D6CYP1A2 | |
| SCHEMBL25045012 | 0.82 | SMN1; SMN2 (0.37) | HSD11B1SMN1; SMN2CYP2D6KMT2AHRH3 | |
| SCHEMBL24891046 | 0.80 | HSD11B1 (0.46) | HSD11B1SMN1; SMN2HRH3 | |
| SCHEMBL22142242 | 0.80 | HSD11B1 (0.33) | HSD11B1SMN1; SMN2HRH3 | |
| SCHEMBL426516 | 0.79 | HTT (0.44) | HSD11B1SMN1; SMN2HTTL3MBTL1CYP2D6 | |
| SCHEMBL12560562 | 0.78 | HSD11B1 (0.43) | HSD11B1SMN1; SMN2CYP2D6TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | SHANGHAI JIA TAN PHARMATECH CO. LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | MTOR, PIK3CA, PIK3CD | HSD11B1 2872/4885SMN1; SMN2 2447/4885HTT 3677/4885 |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | HSD11B1 4721/4885SMN1; SMN2 2165/4885HTT 1608/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | HSD11B1 479/4885SMN1; SMN2 4465/4885HTT 1776/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | HSD11B1 1940/4885SMN1; SMN2 3180/4885HTT 2240/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | HSD11B1 2945/4885SMN1; SMN2 2730/4885HTT 4231/4885 |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | MAVS, SARS1, IRF3 | HSD11B1 4539/4885SMN1; SMN2 2921/4885HTT 3527/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | HSD11B1 1249/4885SMN1; SMN2 696/4885HTT 4098/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | HSD11B1 4721/4885SMN1; SMN2 2165/4885HTT 1608/4885 |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | DDT, CYP3A43, CYP19A1 | HSD11B1 927/4885SMN1; SMN2 2387/4885HTT 141/4885 |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | MAVS, ZC3HAV1, SARS1 | HSD11B1 3046/4885SMN1; SMN2 2646/4885HTT 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.